Chidamide, a Histone Deacetylase Inhibitor, Combined With R‐GemOx in Relapsed/Refractory Diffuse Large B‐Cell Lymphoma (TRUST): A Multicenter, Single‐Arm, Phase 2 Trial

ABSTRACT Background Histone deacetylase (HDAC) inhibitors demonstrated a synergistic anti‐tumor effect with rituximab and chemotherapy in preclinical studies on diffuse large B‐cell lymphoma (DLBCL). This phase 2 trial aimed to evaluate the efficacy and safety of chidamide, an orally active HDAC inh...

Descrición completa

Detalles Bibliográficos

Principais autores:	Qihua Zou, Yuchen Zhang, Hui Zhou, Yulin Lai, Yi Cao, Zhiming Li, Ning Su, Wenyu Li, Huiqiang Huang, Panpan Liu, Xu Ye, Yudan Wu, Huo Tan, Runhui Zheng, Bingyi Wu, Hui Yang, Liye Zhong, Yuhong Lu, Yang Liang, Peng Sun, Lirong Li, Yingxian Liu, Danling Dai, Yi Xia, Qingqing Cai
Formato:	Artigo
Idioma:	Inglês
Publicado:	Wiley 2025-05-01
Series:	Cancer Medicine
Assuntos:	chidamide diffuse large B‐cell lymphoma refractory or relapsed R‐GemOx transplantation‐ineligible
Acceso en liña:	https://doi.org/10.1002/cam4.70919
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!